Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2015', provides an overview of the Microscopic Polyangiitis (MPA)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Microscopic Polyangiitis (MPA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Microscopic Polyangiitis (MPA) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Microscopic Polyangiitis (MPA) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Microscopic Polyangiitis (MPA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Microscopic Polyangiitis (MPA) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Microscopic Polyangiitis (MPA) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Microscopic Polyangiitis (MPA) Overview 6 Therapeutics Development 7 Pipeline Products for Microscopic Polyangiitis (MPA) - Overview 7 Pipeline Products for Microscopic Polyangiitis (MPA) - Comparative Analysis 8 Microscopic Polyangiitis (MPA) - Therapeutics under Development by Companies 9 Microscopic Polyangiitis (MPA) - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Microscopic Polyangiitis (MPA) - Products under Development by Companies 13 Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development 14 Anthera Pharmaceuticals, Inc. 14 Aprogen, Inc. 15 ChemoCentryx, Inc. 16 Epirus Biopharmaceuticals, Inc. 17 Hospira, Inc. 18 Panacea Biotec Limited 19 Sandoz Inc. 20 Microscopic Polyangiitis (MPA) - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 blisibimod - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 CCX-168 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 rituximab biosimilar - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 rituximab biosimilar - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 rituximab biosimilar - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 rituximab biosimilar - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 rituximab biosimilar - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 rituximab biosimilar - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Microscopic Polyangiitis (MPA) - Recent Pipeline Updates 41 Microscopic Polyangiitis (MPA) - Dormant Projects 47 Microscopic Polyangiitis (MPA) - Product Development Milestones 48 Featured News & Press Releases 48 Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 48 Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 48 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 50 Disclaimer 50
List of Tables Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2015 7 Number of Products under Development for Microscopic Polyangiitis (MPA) - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Late Stage Development, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Microscopic Polyangiitis (MPA) - Pipeline by Anthera Pharmaceuticals, Inc., H1 2015 14 Microscopic Polyangiitis (MPA) - Pipeline by Aprogen, Inc., H1 2015 15 Microscopic Polyangiitis (MPA) - Pipeline by ChemoCentryx, Inc., H1 2015 16 Microscopic Polyangiitis (MPA) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 17 Microscopic Polyangiitis (MPA) - Pipeline by Hospira, Inc., H1 2015 18 Microscopic Polyangiitis (MPA) - Pipeline by Panacea Biotec Limited, H1 2015 19 Microscopic Polyangiitis (MPA) - Pipeline by Sandoz Inc., H1 2015 20 Assessment by Monotherapy Products, H1 2015 21 Number of Products by Stage and Target, H1 2015 23 Number of Products by Stage and Mechanism of Action, H1 2015 25 Number of Products by Stage and Route of Administration, H1 2015 27 Number of Products by Stage and Molecule Type, H1 2015 29 Microscopic Polyangiitis (MPA) Therapeutics - Recent Pipeline Updates, H1 2015 41 Microscopic Polyangiitis (MPA) - Dormant Projects, H1 2015 47
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
